Search | IOVS | ARVO Journals

Showing 1 – 20 of 38

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2022

Findings on visual photosensitivity in two phase 1/2 clinical trials of subretinal gene therapy with AGTC-401 and AGTC-402 for CNGB3 and CNGA3 achromatopsia

Rachel M Huckfeldt; Jason Comander; Mark E Pennesi; Paul Yang; Andreas Lauer; Robert Sisk; Edward Averbukh; Eyal Banin; Ninel Z Gregori; Janet L Davis; Byron L Lam; Christine Nichols Kay; Jessica Ijams Wolfing Morgan; Joseph Carroll; Bright Senyo Ashimatey; Matthew Feinsod

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):450. doi:

ARVO Annual Meeting Abstract June 2022

Leber Hereditary Optic Neuropathy Gene Therapy: Adverse Events and Visual Acuity Results of all Patient Groups

Byron L Lam; William J Feuer; Janet L Davis; Vittorio Porciatti; Hong Yu; Robert Levy; Elizabeth Vanner; John Guy

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1576 – A0365. doi:

ARVO Annual Meeting Abstract June 2022

Interim Safety Results in Two Phase 1/2 Open-label, Dose-escalation Clinical Trials of Subretinal Gene Therapy with AGTC-401 (rAAV2tYF-PR1.7-hCNGB3) and AGTC-402 (rAAV2tYF-PR1.7-hCNGA3) in Subjects with Achromatopsia (ACHM)

Alessandro Iannaccone; Mark E Pennesi; Paul Yang; Andreas Lauer; Robert Sisk; Ninel Z Gregori; Janet L Davis; Byron L Lam; Christine Nichols Kay; Mauro Goldbaum; Bright Senyo Ashimatey; Feng Zhu; Matthew Feinsod; Lejla Vajzovic

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2829 – A0345. doi:

ARVO Annual Meeting Abstract June 2021

Progressive shortening of Steady-State Pattern ERG latency with increased LHON severity

Vittorio Porciatti; Diego Alba; William J Feuer; Janet L Davis; Byron L Lam

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):2679. doi:

ARVO Annual Meeting Abstract June 2021

Twelve-month Findings from Two Phase 1/2 Clinical Studies of Subretinal Gene Therapy Drugs for Achromatopsia

Mark E Pennesi; Paul Yang; Andreas Lauer; Robert A Sisk; Jason M Comander; Rachel M. Huckfeldt; Edward Averbuhk; Eyal Banin; Ninel Gregori; Janet L Davis; Byron L Lam; Christine Kay; Erin Leone; Deanine Halliman; Nnenna Ihekoromadu; Matthew Feinsod

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3321. doi:

ARVO Annual Meeting Abstract June 2020

A Novel Method to Detect and Monitor Retinal Vasculitis Using Swept Source OCT Angiography

Jila Noorikolouri; Yingying Shi; Jin Yang; Thomas Albini; Giovanni Gregori; Philip J Rosenfeld; Janet L Davis

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4333. doi:

ARVO Annual Meeting Abstract July 2019

Prevalence of Retinal Gene Mutations in Patients Undergoing Evaluation for Autoimmune Retinopathy with Antiretinal Antibodies

Jila Noorikolouri; Janet L Davis

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6674. doi:

ARVO Annual Meeting Abstract July 2019

Polymerase Chain Reaction for the Diagnosis of Chorioretinal Infections: Comparative Study of Testing in a Single Institution

Janet L Davis; Sulaiman Alhumaid

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):823. doi:

ARVO Annual Meeting Abstract July 2019

Polymerase Chain Reaction in the Diagnosis of Toxoplasma gondii Chorioretinitis

JOHN W HINKLE; Sulaiman Alhumaid; Darlene Miller; Janet L Davis; Thomas A Albini

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):824. doi:

ARVO Annual Meeting Abstract July 2019

OCT-Angiography in Vogt Koyanagi Harada Syndrome: A Comparative Cross Sectional Imaging Analysis

Justin Yamanuha; Janet L Davis; Jila Noorikolouri

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):4553. doi:

ARVO Annual Meeting Abstract July 2019

Gene Therapy for Leber Hereditary Optic NeuropathY An update of Where We Stand (Clinicaltrials.gov number: NCT02161380)

John Guy; William Feuer; Janet L Davis; Vittorio Porciatti; Philip Gonzalez; Rajeshwari D Koilkonda; Huijun Yuan; Byron L Lam

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3602. doi:

ARVO Annual Meeting Abstract July 2019

Preliminary results in 18 patients undergoing retinal gene therapy for X-linked retinitis pigmentosa with codon-optimized AAV8-RPGR

Robert E MacLaren; Janet L Davis; Ninel Gregori; Jasmina Cehajic-Kapetanovic; Byron L Lam; Andrew Lotery; Cristina Martinez-Fernandez dela Camara; Anika Nanda; Anna Paola Salvetti; Paulo Stanga; Kanmin Xue

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):1329. doi:

ARVO Annual Meeting Abstract July 2018

Pars plana vitrectomy for the treatment of uveitis

Christopher Ryan Henry; Matthias Becker; Yang Yongsheng; Janet L. Davis

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4199. doi:

ARVO Annual Meeting Abstract July 2018

Dissociations of the fluocinolone acetonide implant: experience from long-term follow-up during the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study

Elizabeth A Sugar; Janet A Holbrook; Alyce E Burke; Glenn J Jaffe; Albert T Vitale; Janet L. Davis; Douglas A Jabs

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):417. doi:

ARVO Annual Meeting Abstract June 2017

Choroideremia Gene Therapy Phase II Clinical Trial: 6-Month Results

Byron L Lam; Jennifer Verriotto; Ninel Gregori; Janet L Davis

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):3386. doi:

ARVO Annual Meeting Abstract June 2017

Neutralizing Antibodies Against Adeno-associated virus (AAV)2 Capsids in LHON Gene Therapy Clinical Trial Patients: An Update

Rajeshwari D Koilkonda; William J Feuer; Joyce Schiffman; Janet L Davis; Vittorio Porciatti; Phillip Gonzalez; Byron L Lam; John Guy

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):3861. doi:

ARVO Annual Meeting Abstract June 2017

Gene Therapy for LHON Suppresses Neurodegeneration

John Guy; Rajeshwari D Koilkonda; William J Feuer; Janet L Davis; Vittorio Porciatti; Phillip Gonzalez; Huijan Yuan; Byron L Lam

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4492. doi:

ARVO Annual Meeting Abstract September 2016

Assessment of Neutralizing Antibodies Against Adeno-associated virus (AAV)2 Capsids in Serum and Ocular Fluid Samples of Leber’ Hereditary Optic Neuropathy (LHON) Gene Therapy Clinical Trial Patients

Rajeshwari D Koilkonda; William J Feuer; Joyce C Schiffman; Janet L Davis; Vittorio Porciatti; Phillip Gonzalez; Byron L Lam; John Guy

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5083. doi:

ARVO Annual Meeting Abstract September 2016

LHON Gene Therapy Clinical Trial: Year 2 Results

John Guy; William J Feuer; Janet L Davis; Vittorio Porciatti; Rajeshwari D Koilkonda; Huijun Yuan; Byron L Lam; William Hauswirth

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5086. doi:

ARVO Annual Meeting Abstract September 2016

Endophthalmitis Caused by Corynebacterium Species: Clinical Features, Antibiotic Susceptibility, and Treatment Outcomes

Nicolas Alessandro Yannuzzi; Ajay E. Kuriyan; Jayanth Sridhar; Harry W Flynn; Laura Huang; William E Smiddy; Janet L Davis; Thomas Arno Albini; Audina M Berrocal; Darlene Miller

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):6385. doi:

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Findings on visual photosensitivity in two phase 1/2 clinical trials of subretinal gene therapy with AGTC-401 and AGTC-402 for CNGB3 and CNGA3 achromatopsia

Leber Hereditary Optic Neuropathy Gene Therapy: Adverse Events and Visual Acuity Results of all Patient Groups

Interim Safety Results in Two Phase 1/2 Open-label, Dose-escalation Clinical Trials of Subretinal Gene Therapy with AGTC-401 (rAAV2tYF-PR1.7-hCNGB3) and AGTC-402 (rAAV2tYF-PR1.7-hCNGA3) in Subjects with Achromatopsia (ACHM)

Progressive shortening of Steady-State Pattern ERG latency with increased LHON severity

Twelve-month Findings from Two Phase 1/2 Clinical Studies of Subretinal Gene Therapy Drugs for Achromatopsia

A Novel Method to Detect and Monitor Retinal Vasculitis Using Swept Source OCT Angiography

Prevalence of Retinal Gene Mutations in Patients Undergoing Evaluation for Autoimmune Retinopathy with Antiretinal Antibodies

Polymerase Chain Reaction for the Diagnosis of Chorioretinal Infections: Comparative Study of Testing in a Single Institution

Polymerase Chain Reaction in the Diagnosis of Toxoplasma gondii Chorioretinitis

OCT-Angiography in Vogt Koyanagi Harada Syndrome: A Comparative Cross Sectional Imaging Analysis

Gene Therapy for Leber Hereditary Optic NeuropathY An update of Where We Stand (Clinicaltrials.gov number: NCT02161380)

Preliminary results in 18 patients undergoing retinal gene therapy for X-linked retinitis pigmentosa with codon-optimized AAV8-RPGR

Pars plana vitrectomy for the treatment of uveitis

Dissociations of the fluocinolone acetonide implant: experience from long-term follow-up during the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study

Choroideremia Gene Therapy Phase II Clinical Trial: 6-Month Results

Neutralizing Antibodies Against Adeno-associated virus (AAV)2 Capsids in LHON Gene Therapy Clinical Trial Patients: An Update

Gene Therapy for LHON Suppresses Neurodegeneration

Assessment of Neutralizing Antibodies Against Adeno-associated virus (AAV)2 Capsids in Serum and Ocular Fluid Samples of Leber’ Hereditary Optic Neuropathy (LHON) Gene Therapy Clinical Trial Patients

LHON Gene Therapy Clinical Trial: Year 2 Results

Endophthalmitis Caused by Corynebacterium Species: Clinical Features, Antibiotic Susceptibility, and Treatment Outcomes

To View More...

You must be signed into an individual account to use this feature.